These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30600305)

  • 1. Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy.
    González-Aldaco K; Torres-Reyes LA; Ojeda-Granados C; José-Ábrego A; Fierro NA; Román S
    Ann Hepatol; 2018 Oct; 17(6):908-919. PubMed ID: 30600305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection.
    Xiang Y; Tang JJ; Tao W; Cao X; Song BL; Zhong J
    J Virol; 2015 Jul; 89(13):6805-16. PubMed ID: 25903345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.
    Lonardo A; Adinolfi LE; Restivo L; Ballestri S; Romagnoli D; Baldelli E; Nascimbeni F; Loria P
    World J Gastroenterol; 2014 Jun; 20(23):7089-103. PubMed ID: 24966582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic alterations and hepatitis C: From bench to bedside.
    Chang ML
    World J Gastroenterol; 2016 Jan; 22(4):1461-76. PubMed ID: 26819514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.
    Hartlage AS; Walker CM; Kapoor A
    J Virol; 2020 May; 94(10):. PubMed ID: 32102885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
    Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
    Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
    Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
    Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput approaches to unravel hepatitis C virus-host interactions.
    Colpitts CC; El-Saghire H; Pochet N; Schuster C; Baumert TF
    Virus Res; 2016 Jun; 218():18-24. PubMed ID: 26410623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation and evasion of antiviral innate immunity by hepatitis C virus.
    Horner SM
    J Mol Biol; 2014 Mar; 426(6):1198-209. PubMed ID: 24184198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy.
    Li H; Huang MH; Jiang JD; Peng ZG
    World J Gastroenterol; 2018 Dec; 24(47):5297-5311. PubMed ID: 30598575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate immunity and HCV.
    Heim MH
    J Hepatol; 2013 Mar; 58(3):564-74. PubMed ID: 23063572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs regulate the immunometabolic response to viral infection in the liver.
    Singaravelu R; O'Hara S; Jones DM; Chen R; Taylor NG; Srinivasan P; Quan C; Roy DG; Steenbergen RH; Kumar A; Lyn RK; Özcelik D; Rouleau Y; Nguyen MA; Rayner KJ; Hobman TC; Tyrrell DL; Russell RS; Pezacki JP
    Nat Chem Biol; 2015 Dec; 11(12):988-93. PubMed ID: 26479438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.
    Casey JL; Feld JJ; MacParland SA
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy Implications of Hepatitis C Virus Genetic Diversity.
    Martinez MA; Franco S
    Viruses; 2020 Dec; 13(1):. PubMed ID: 33383891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organ system view of the hepatic innate immunity in HCV infection.
    Bang BR; Elmasry S; Saito T
    J Med Virol; 2016 Dec; 88(12):2025-2037. PubMed ID: 27153233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of hepatic innate immunity by hepatitis C virus.
    Horner SM; Gale M
    Nat Med; 2013 Jul; 19(7):879-88. PubMed ID: 23836238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.
    Rockey DC; Friedman SL
    Gastroenterology; 2021 Apr; 160(5):1502-1520.e1. PubMed ID: 33529675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate and Adaptive Immune Responses in Chronic HCV Infection.
    Dustin LB
    Curr Drug Targets; 2017; 18(7):826-843. PubMed ID: 26302811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
    Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
    Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus relies on lipoproteins for its life cycle.
    Grassi G; Di Caprio G; Fimia GM; Ippolito G; Tripodi M; Alonzi T
    World J Gastroenterol; 2016 Feb; 22(6):1953-65. PubMed ID: 26877603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.